Skip to main content
. 2018 Jan 9;11:731. doi: 10.3389/fnins.2017.00731

Table 3.

Validation miRNAs.

miRNA Count abundance log2FoldChange (control vs. sALS) Increase/Decrease
Oasis 2.0 Genboree Oasis 2.0 Genboree Control vs. sALS
miR-124-3p 13 24 2.09 3.17 Increased
miR-127-3p 50 89 1.65 1.38 Increased
miR-143-3p 2111 3882 0.58 0.48 Increased
miR-125b-2-3p 1455 1424 0.58 0.62 Increased
miR-9-5p 93 164 1.91 1.64 Increased
miR-27b-3p 604 1047 0.74 0.62 Increased
miR-486-5p 377 2139 −1.13 −0.85 Decreased
Let-7f-5p 369 704 −0.33 −0.42 Decreased
miR-16-5p 78 152 −0.76 −0.77 Decreased
miR-28-3p 77 142 −0.58 −0.59 Decreased
miR-146a-5p 74 148 −0.85 −0.82 Decreased
miR-150-5p 48 95 −1.53 −1.39 Decreased
miR-378a-3p 33 73 −0.9 −0.95 Decreased
miR-142-5p 30 39 −1.23 −1.25 Decreased
miR-92a-5p 605 1190 −0.52 −0.54 Decreased

Values in blue indicate significantly differentially expressed miRNAs that were identified by Oasis 2.0 only. Values in yellow indicate significantly differentially expressed miRNAs that were identified by both Oasis 2.0 and Genboree. Results were filtered at corrected p-value < 0.05. sALS, sporadic amyotrophic lateral sclerosis.